良性疾病 › 貧血
鐵芽球性貧血
Sideroblastic Anemia
概覽
Buzzwords → Dx
| Buzzword | Diagnosis / Clue |
|---|---|
| Ringed sideroblasts on Prussian blue stain | Diagnostic |
| Microcytic-to-macrocytic dimorphic anemia | Sideroblastic gestalt |
| High serum iron + high ferritin + high TSAT (vs IDA pattern) | Iron overload despite anemia |
| X-linked ALAS2 mutation | Hereditary; B6 (pyridoxine) responsive |
| SF3B1 mutation + ringed sideroblasts | MDS-SF3B1 (or MDS-RS); favorable prognosis MDS |
| Lead poisoning + basophilic stippling | Acquired sideroblastic + neuropathy |
| Isoniazid use without B6 | Reversible sideroblastic |
| Alcoholism / chronic | Sideroblastic with B6 antagonism |
| Copper deficiency (zinc excess, gastric bypass, parenteral nutrition) | Sideroblastic with neutropenia + ataxia + myelopathy |
| Chloramphenicol | Reversible sideroblastic |
分類與診斷
Diagnostic Criteria
- Ringed sideroblasts ≥15 % of erythroblasts on Prussian blue iron stain (or ≥5 % with SF3B1 mutation = MDS-RS per WHO 5e).
- Iron studies: elevated serum iron, ferritin, TSAT (vs IDA which has low values).
- Marrow biopsy + cytogenetics + NGS to subtype.
- Genetic testing for hereditary (ALAS2, SLC25A38, GLRX5, ATP12, TRNT1, ABCB7).
- Lead level if exposure suspected (children with pica, occupational, water sources).
- Drug review (INH, alcohol, chloramphenicol).
- Copper, ceruloplasmin if neuropathy + neutropenia.
Workup
- CBC + smear + retic (basophilic stippling in lead).
- Iron studies (Fe, TIBC, ferritin, TSAT).
- B12, folate, B6 (pyridoxine).
- Lead level.
- Marrow biopsy with Prussian blue stain + karyotype + NGS panel (SF3B1, others).
- Copper + ceruloplasmin if non-clonal sideroblastic suspected.
- Drug history + alcohol use review.
治療
Treatment Algorithm
flowchart TD
A[Sideroblastic anemia confirmed] --> B{Cause}
B -- hereditary X-linked ALAS2 --> C[Pyridoxine 50-200 mg/d trial<br>often dramatic response]
B -- MDS-RS / SF3B1 mutation --> D[Luspatercept first-line<br>COMMANDS trial<br>or HMA in higher-risk MDS]
B -- lead poisoning --> E[Remove exposure + chelation<br>EDTA / DMSA / dimercaprol]
B -- isoniazid / alcohol / chloramphenicol / drug --> F[Discontinue / replace<br>+ pyridoxine]
B -- copper deficiency --> G[Copper repletion<br>oral or parenteral; remove zinc excess]
C --> H[Iron overload monitoring<br>chelation if ferritin >1000 or LIC high]
D --> H
H --> I[Deferasirox / deferoxamine / deferiprone<br>per iron loading]
陷阱與考點
Pearls / Pitfalls
- High iron + high ferritin + low Hb = sideroblastic, not IDA. Don't give iron — worsens overload.
- Hereditary X-linked sideroblastic anemia can dramatically respond to pyridoxine (B6) — always trial in suspected hereditary cases.
- MDS-SF3B1 (MDS-RS) has favorable prognosis among MDS — treat with luspatercept (COMMANDS) or watch.
- Lead poisoning: classical microcytic with basophilic stippling, abdominal pain, peripheral neuropathy (wrist drop), behavioral/cognitive. Pediatric pica + water/paint exposure.
- Isoniazid (INH) depletes B6 → sideroblastic + peripheral neuropathy. Always co-prescribe pyridoxine 25–50 mg/d with INH.
- Copper deficiency (post-gastric bypass, zinc-rich denture cream, parenteral nutrition without copper) → sideroblastic + neutropenia + ataxia + myelopathy. Replete copper.
- Iron overload is universal in chronic sideroblastic — iron chelation when ferritin >1000 or hepatic iron concentration high. Avoid additional iron supplements.
- Alcohol chronic — multifactorial (sideroblastic + folate deficiency + direct toxicity) — abstinence + nutrition.
- Chloramphenicol — reversible sideroblastic with high doses; rarely used now.
延伸
Cross-references
- IDA — opposite iron pattern
- MDS-SF3B1 — clonal sideroblastic
- Iron Chelation
- Iron Studies — sideroblastic pattern
- Anemia Workup
相關題目
- Q-121 — Sideroblastic anemia — pyridoxine response
- Q-122 — Sideroblastic anemia — copper deficiency mimic
- Q-123 — Sideroblastic anemia — lead poisoning
來源
Sources
Footnotes
-
Bottomley SS, Fleming MD. Sideroblastic Anemia: Diagnosis and Management. Hematology/Oncology Clinics of North America 2014;28(4):653–670. doi:10.1016/j.hoc.2014.04.008. ↩